Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically painful and filled with fluid or pus. AbbVie’s Humira (adalimumab) was the only FDA-approved therapy for HS until October 2023, when the FDA approved Cosentyx for moderate to severe HS, the same patient population for which Humira is specifically approved. Notably, depending on their specific symptoms, patients may initially receive off-label treatment with other agents, such as antibiotics and immunosuppressants, before their physician prescribes these approved biologics. Alternative targeted therapies (e.g., Johnson & Johnson Innovative Medicine’s Remicade [infliximab]) may be used off-label for more severe disease and for patients who do not respond to Humira or Cosentyx. This content will provide manufacturers of current treatments, as well as those developing novel HS agents, with insights into the use of various drugs for HS and market trends in this area.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HS patients?
- How has Humira been integrated into the treatment algorithm, and what is its source of business?
- What percentage of HS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
Markets covered: United States
Key drugs: Humira, infliximab biosimilars, Enbrel, Stelara, Simponi, clindamycin, doxycycline, acitretin, methotrexate, dapsone, cyclosporine, tacrolimus, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi, Ilumya, Cimzia
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
